A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Scheuplein, Felix ^a   Thariath, Abraham ^a   Macdonald, Susan ^a   Truneh, Alemseged ^a   Mashal, Robert ^a   Schaub, Robert ^a  

^a NKT Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC GAMMA RI; FC RECEPTOR; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY NKTT120; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; INVARIANT NATURAL KILLER T CELL; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INFLAMMATION; MACACA FASCICULARIS; NATURAL KILLER T-CELLS;

EID: 84884698633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076692     Document Type: Article

References (20)

1. Van Kaer L, Parekh VV, Wu L, (2010) Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res 343: 43-55. PubMed: 20734065.
2. Brennan PJ, Brigl M, Brenner MB, (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13: 101-117. doi:10.1038/nri3369. PubMed: 23334244.
3. Bienemann K, Iouannidou K, Schoenberg K, Krux F, Reuther S, et al. (2011) iNKT cell frequency in peripheral blood of Caucasian children and adolescent: the absolute iNKT cell count is stable from birth to adulthood. Scand J Immunol 74: 406-411. doi:10.1111/j.1365-3083.2011.02591.x. PubMed: 21671972.
4. Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, et al. (2007) Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122: 1-14. doi:10.1111/j.1365-2567.2007.02647.x. PubMed: 17662044.
5. Van Kaer L, (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19: 354-364. doi:10.1016/j.coi.2007.03.001. PubMed: 17428648.
6. Bendelac A, Savage PB, Teyton L, (2007) The biology of NKT cells. Annu Rev Immunol 25: 297-336. doi:10.1146/annurev.immunol.25.022106.141711. PubMed: 17150027.
7. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L, (2008) CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 20: 358-368. doi:10.1016/j.coi.2008.03.018. PubMed: 18501573.
8. Wu L, Van Kaer L, (2009) Natural killer T cells and autoimmune disease. Curr Mol Med 9: 4-14. doi:10.2174/156652409787314534. PubMed: 19199937.
9. Field JJ, Lin G, Okam MM, Majerus E, Keefer J, et al. (2013) Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood, 121: 3329-34. PubMed: 23377438.
10. Field JJ, Nathan DG, Linden J, (2011) Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol 140: 177-183. doi:10.1016/j.clim.2011.03.002. PubMed: 21429807.
11. Wallace KL, Linden J, (2010) Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116: 5010-5020. doi:10.1182/blood-2010-06-290643. PubMed: 20798237.
12. Wallace KL, Marshall MA, Ramos SI, Lannigan JA, Field JJ, et al. (2009) NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 114: 667-676. doi:10.1182/blood-2009-02-205492. PubMed: 19433855.
13. Exley MA, Hou R, Shaulov A, Tonti E, Dellabona P, et al. (2008) Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol 38: 1756-1766. doi:10.1002/eji.200737389. PubMed: 18493987.
14. Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, et al. (2011) A variant human IgG1-Fc mediates improved ADCC. Protein Eng Des Sel 24: 671-678. doi:10.1093/protein/gzr015. PubMed: 21596686.
15. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, et al. (2000) Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 30: 1919-1928. doi:10.1002/1521-4141(200007)30:7. PubMed: 10940881.
16. Levêque D, Wisniewski S, Jehl F, (2005) Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 25: 2327-2343. PubMed: 16080460.
17. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ, (1995) Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 38: 1242-1251. doi:10.1002/art.1780380912. PubMed: 7575719.
18. Haraguchi K, Takahashi T, Hiruma K, Kanda Y, Tanaka Y, et al. (2004) Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 34: 595-602. doi:10.1038/sj.bmt.1704582. PubMed: 15300228.
19. Beziat V, Nguyen S, Exley M, Achour A, Simon T, et al. (2010) Shaping of iNKT cell repertoire after unrelated cord blood transplantation. Clin Immunol 135: 364-373. doi:10.1016/j.clim.2010.01.010. PubMed: 20153980.
20. Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, et al. (2012) Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 120: 2144-2154. doi:10.1182/blood-2012-01-404673. PubMed: 22730537.